SITC 2022 | The latest developments in immunotherapeutic targeting myeloid cells

Judith Varner, PhD, University of California, San Diego, CA, discusses the latest developments in targeting myeloid cells for cancer immunotherapy and are there any therapeutic targets for myeloid cells. The inhibition of TRIM2, a cell surface receptor presented on select myeloid cells in tumors, have been shown to promote clinical benefit. Efforts to inhibit cytokines that recruit granulocytes are also underway. Antibodies are being developed against checkpoints on myeloid cells that can inhibit T-cell activation. CAR-macrophages have been developed to stimulate immune response and directly kill tumor cells and are currently in early Phase clinical trials. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.